Summit Creek Advisors LLC Sells 2,131 Shares of Medpace Holdings, Inc. $MEDP

Summit Creek Advisors LLC lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,101 shares of the company’s stock after selling 2,131 shares during the quarter. Medpace accounts for approximately 2.2% of Summit Creek Advisors LLC’s investment portfolio, making the stock its 22nd biggest holding. Summit Creek Advisors LLC owned 0.18% of Medpace worth $15,725,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Teacher Retirement System of Texas increased its position in shares of Medpace by 2.0% in the first quarter. Teacher Retirement System of Texas now owns 7,424 shares of the company’s stock valued at $2,262,000 after acquiring an additional 144 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in Medpace by 16.1% during the first quarter. Crossmark Global Holdings Inc. now owns 2,270 shares of the company’s stock worth $692,000 after purchasing an additional 315 shares during the period. Linden Thomas Advisory Services LLC raised its stake in Medpace by 1.9% in the first quarter. Linden Thomas Advisory Services LLC now owns 4,746 shares of the company’s stock valued at $1,446,000 after buying an additional 87 shares during the period. Alps Advisors Inc. lifted its position in shares of Medpace by 10.0% in the first quarter. Alps Advisors Inc. now owns 1,098 shares of the company’s stock valued at $335,000 after buying an additional 100 shares during the last quarter. Finally, Covey Capital Advisors LLC acquired a new position in shares of Medpace during the 1st quarter worth approximately $1,261,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Activity at Medpace

In related news, CEO August J. Troendle sold 36,196 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $475.90, for a total value of $17,225,676.40. Following the transaction, the chief executive officer directly owned 925,799 shares in the company, valued at $440,587,744.10. This trade represents a 3.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President Jesse J. Geiger sold 19,460 shares of the business’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $605.12, for a total transaction of $11,775,635.20. Following the sale, the president directly owned 36,503 shares of the company’s stock, valued at approximately $22,088,695.36. The trade was a 34.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 94,708 shares of company stock worth $50,761,481 over the last ninety days. 20.30% of the stock is owned by corporate insiders.

Medpace Price Performance

Shares of Medpace stock opened at $598.81 on Thursday. The company’s 50 day moving average price is $523.07 and its two-hundred day moving average price is $409.00. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $625.00. The firm has a market capitalization of $16.87 billion, a P/E ratio of 41.87, a P/E/G ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping the consensus estimate of $3.50 by $0.36. The business had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm’s revenue was up 23.7% compared to the same quarter last year. During the same period last year, the company earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Ratings Changes

MEDP has been the topic of a number of research reports. Robert W. Baird set a $613.00 price objective on Medpace in a report on Friday, October 24th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research report on Friday, October 31st. TD Cowen increased their price target on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research report on Friday, October 24th. Rothschild & Co Redburn lowered Medpace from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Finally, Cowen reaffirmed a “sell” rating on shares of Medpace in a report on Friday, October 24th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, nine have given a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $475.90.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.